Shigeru Kawakami

ORCID: 0000-0001-8765-2463
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • RNA Interference and Gene Delivery
  • Virus-based gene therapy research
  • Advanced biosensing and bioanalysis techniques
  • Immunotherapy and Immune Responses
  • Nanoparticle-Based Drug Delivery
  • Ultrasound and Hyperthermia Applications
  • Viral gastroenteritis research and epidemiology
  • Immune Response and Inflammation
  • CRISPR and Genetic Engineering
  • Drug Transport and Resistance Mechanisms
  • Retinoids in leukemia and cellular processes
  • Glycosylation and Glycoproteins Research
  • Monoclonal and Polyclonal Antibodies Research
  • Nanoplatforms for cancer theranostics
  • Ultrasound and Cavitation Phenomena
  • Photoacoustic and Ultrasonic Imaging
  • Renal and related cancers
  • Advanced Drug Delivery Systems
  • Dendrimers and Hyperbranched Polymers
  • Antibiotics Pharmacokinetics and Efficacy
  • Lipid Membrane Structure and Behavior
  • Pluripotent Stem Cells Research
  • Extracellular vesicles in disease
  • NF-κB Signaling Pathways
  • Drug Solubulity and Delivery Systems

Nagasaki University
2016-2025

Kyoto University
2007-2017

Kyoto Pharmaceutical University
2005-2014

Japan Science and Technology Agency
2013

Japan Society for the Promotion of Science
2010

Waseda University
2003

Kyushu University
1995

ConocoPhillips (United States)
1984

Chitosan has the potential to be a biocompatible gene carrier. However, transfection efficiency of chitosan is low because slow endosomal escape rate. The buffering capacity histidine in pH range would help plasmid DNA (pDNA) from endosomes. In this study, was introduced into improve efficiency. and were linked by disulfide bonds provided 2-iminothiolane cysteine. complexes prepared mixing or histidine-modified with DNA. A broader observed, cellular uptake chitosan/pDNA higher than that...

10.1021/bc1000609 article EN Bioconjugate Chemistry 2010-05-25

Lipid nanoparticles (LNPs) are currently in the spotlight as delivery systems for mRNA therapeutics and have been used Pfizer/BioNTech Moderna COVID-19 vaccines. mRNA-LNP formulations indicated to require strict control, including maintenance at fairly low temperatures during their transport storage. Since it is a new pharmaceutical modality, there lack of information on systematic investigation how storage handling conditions affect physicochemical properties mRNA-LNPs protein expression...

10.3390/pharmaceutics14112357 article EN cc-by Pharmaceutics 2022-10-31

To optimize a receptor-mediated and cell-selective gene transfer with polyethyleneimine (PEI)-based vector, we synthesized three galactosylated PEIs (Gal-PEI) different molecular weights (PEI(1800), PEI(10,000), PEI(70,000)) investigated their potential as targetable vector to asialoglycoprotein receptor-positive cells. All PEI derivatives formed complexes plasmid DNA (pDNA), whereas the particle size of complex became smaller on increasing weight PEI. Transfection efficiency in HepG2 cells...

10.1016/s1525-0016(02)00053-9 article EN cc-by-nc-nd Molecular Therapy 2003-02-01

Transposons are promising systems for somatic gene integration because they can not only integrate exogenous genes efficiently, but also be delivered to a variety of organs using range transfection methods. piggyBac (PB) transposon has high transposability in mammalian cells vitro, and been used genetic preclinical studies. However, the PB vivo demonstrated yet. Here, we PB-mediated sustained expression adult mice. We constructed PB-based plasmid DNA (pDNA) containing reporter [firefly...

10.1038/mt.2009.302 article EN cc-by-nc-nd Molecular Therapy 2010-01-26

Delivery of messenger RNA (mRNA) using lipid nanoparticles (LNPs) is expected to be applied various diseases following the successful clinical use mRNA COVID-19 vaccines. This study aimed evaluate effect cholesterol molar percentage mRNA-LNPs on protein expression in hepatocellular carcinoma-derived cells and liver after intramuscular or subcutaneous administration mice. For with percentages reduced 10 mol% 20 mol%, we formulated neutral charge particles a diameter approximately 100 nm...

10.1016/j.xphs.2022.12.026 article EN cc-by-nc-nd Journal of Pharmaceutical Sciences 2022-12-31
Coming Soon ...